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Gastric inhibitory polypeptide (GIP) exhibits potent insu-
linotropic effects on b-cells and anabolic effects on
bone formation and fat accumulation. We explored the
impact of reduced GIP levels in vivo on glucose homeo-
stasis, bone formation, and fat accumulation in a novel
GIP-GFP knock-in (KI) mouse. We generated GIP-GFP
KI mice with a truncated prepro-GIP gene. The pheno-
type was assessed in heterozygous and homozygous
states in mice on a control fat diet and a high-fat diet
(HFD) in vivo and in vitro. Heterozygous GIP-GFP KI
mice (GIP-reduced mice [GIPgfp/+]) exhibited reduced
GIP secretion; in the homozygous state (GIP-lacking
mice [GIPgfp/gfp]), GIP secretion was undetectable.
When fed standard chow, GIPgfp/+ and GIPgfp/gfp mice
showed mild glucose intolerance with decreased insulin
levels; bone volume was decreased in GIPgfp/gfp mice
and preserved in GIPgfp/+ mice. Under an HFD, glucose
levels during an oral glucose tolerance test were similar
in wild-type, GIPgfp/+, and GIPgfp/gfp mice, while insulin
secretion remained lower. GIPgfp/+ and GIPgfp/gfp mice
showed reduced obesity and reduced insulin resistance,
accompanied by higher fat oxidation and energy expen-
diture. GIP-reduced mice demonstrate that partial re-
duction of GIP does not extensively alter glucose
tolerance, but it alleviates obesity and lessens the de-
gree of insulin resistance under HFD conditions, sug-
gesting a potential therapeutic value.
Gastric inhibitory polypeptide (GIP) is a 42–amino acid
polypeptide produced by enteroendocrine K cells, which
are located mainly in the upper parts of the small intes-
tine. Its main secretagogues are glucose and, even
more intensely, fats that reach the intestinal lumen soon
after food intake (1). Following secretion, the hormone
exerts its effects through speciﬁc, G-protein–coupled
receptors located mainly in the stomach, pancreas, central
nervous system, bone, and adipose tissue (2,3). Apart
from its role in the inhibition of gastric acid secretion
(4), GIP exhibits potent glucose-dependent insulinotropic
action (5,6), and, therefore, it is classiﬁed as an incretin (3).
In addition to its insulinotropic effect, in the absence of
which glucose intolerance develops (7), GIP stimulates islet
growth (8) and proliferation of b-cells (9), and reduces
b-cell apoptosis (10,11). Studies of GIP receptor (GIPR)
knock-out (GIPRKO) mice (7) describe GIP as an obesity-
promoting factor in high-fat diet (HFD) conditions, and
show that deletion of GIPR signaling causes resistance to
obesity (12) but leads to osteoporosis (13), revealing an
important role of GIP in bone metabolism. However, in
these studies, as well as in a model of GIPR antagonism
(14), the reported changes were focused on disrupted or
blocked GIPR signaling. The condition of reduced GIP se-
cretion and how it affects the pancreatic and extrapancre-
atic effects of GIP remain unclear.
The aim of the current study is to explore the potential
of reduced GIP levels in vivo, and to deﬁne the impact on
glucose homeostasis, bone formation, and fat accumula-
tion in a novel GIP–green ﬂuorescent protein (GFP)
knock-in (KI) mouse model characterized by truncation
of the prepro-GIP gene and insertion of a GFP sequence
(15). The model was developed for the purpose of visual-
ization and identiﬁcation of K cells and exhibits reduced
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or absent GIP secretion in heterozygous GIP-reduced mice
and homozygous or GIP-lacking mice, respectively. Estab-
lishing the phenotype of the heterozygous GIP-reduced
mouse is important to understand the possible beneﬁts
of a limited reduction of GIP secretion.
RESEARCH DESIGN AND METHODS
Animals
Male GIP-GFP KI mice and wild-type (WT) littermates
were used in all experiments. GIP-GFP KI mice were
generated as described previously (15). The animals were
maintained under conditions of a 12 h light/dark cycle,
with free access to water and food, unless indicated other-
wise. Starting from 7 weeks of age, the mice were divided
into the following two groups: the control fat diet (CFD)
group, receiving food with 10% of fat and energy density
of 3.8 kcal/g (catalog no. D12450B; Research Diets Inc.,
New Brunswick, NJ); and the HFD group, receiving food
with 60% of fat and energy density of 5.2 kcal/g (catalog
no. D12492; Research Diets Inc.). In total, six groups of
mice (ﬁve to six mice per group) were used throughout
the study: WT mice on CFD, heterozygous GIP-GFP KI
mice (GIPgfp/+) on CFD, homozygous GIP-GFP KI mice
(GIPgfp/gfp) on CFD, WT on HFD, GIPgfp/+ mice on HFD,
and GIPgfp/gfp on HFD. After 8 weeks of CFD or HFD
feeding, the animals were used in the experiments listed
below. Maintenance of the mice and all experimental pro-
cedures were approved by Kyoto University Animal Care
Committee.
Expression Levels of GIPR mRNA
After standard chow feeding or at least 8 weeks of CFD
and HFD feeding, mice were killed by cervical dislocation,
and the pancreas and white (visceral) adipose tissue were
harvested. The white adipose tissue was frozen immedi-
ately in liquid nitrogen and stored at 280°C until further
use; the pancreas was digested using the collagenase
method, and islets were obtained. Islet mRNA (RNeasy
Mini Kit; Qiagen, Hilden, Germany) and adipose tissue
mRNA (RNeasy Lipid Tissue Mini Kit; Qiagen) were
extracted and cDNA was synthesized by reverse transcrip-
tion (SuperScript II; Invitrogen, Carlsbad, CA). GIPR
mRNA expression levels were quantiﬁed by semiquantita-
tive real-time PCR (AB StepOne Plus Real Time PCR; Ap-
plied Biosystems, Foster City, CA) using GIPR forward
and reverse primers with the following sequence: 59-
CCTCCACTGGGTCCCTACAC-39 (forward primer) and
59-GATAAACACCCTCCACCAGTAG-39 (reverse primer).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA was used as an internal control. The sequences
of GAPDH forward and reverse primers are as follows: 59-
AAATGGTGAAGGTCGGTGTG-39 for the forward primer,
and 59-TCGTTGATGGCAACAATCTC-39 for the reverse
primer.
Measurement of GIP Content and Protein Content
Mice were killed at 6 weeks of age by cervical dislocation,
intestine samples were taken and washed in PBS,
weighed, and, after overnight extraction with 5 mL/g
acid ethanol (at 4°C), GIP content was measured by ELISA
(Millipore Corp., Billerica, MA). Protein content was mea-
sured using Bradford Protein Assay (Bio-Rad, Hercules,
CA). In brief, dye reagent was diluted, and protein (albu-
min) standards were made in duplicate. Standards and
intestine samples were loaded on a microtiter plate, in-
cubated at room temperature for 5 min, and absorbance
was measured at 595 nm. GIP content was expressed as
GIP content per protein content.
Bone Histomorphometry
Six-week-old mice that had been fed standard chow were
prepared for bone histomorphometry measurement by
subcutaneous injection of 25 mg/kg tetracycline hydro-
chloride (Sigma-Aldrich, St. Louis, MO) 4 days before they
were killed and 10 mg/kg calcein (Dojindo, Kumamoto,
Japan) 2 days before they were killed. Animals were killed
by cervical dislocation, and tibiae were removed and ﬁxed
with 70% ethanol. Further processing of tibiae samples
(muscle removing, dehydration in graded concentration of
ethanol, Villanueva bone staining, and embedding in
methyl methacrylate), preparation of frontal plane sec-
tions of tibiae, and bone histomorphometry measurement
using a semiautomatic image-analyzing system (System
Supply, Nagano, Japan) were performed by Niigata Bone
Science Institute, Niigata, Japan.
Oral Glucose Tolerance Test and Measurement of
Hormones
Following 8 weeks of CFD and HFD, the mice underwent
an oral glucose tolerance test (OGTT). The fasting period
(overnight fasting) was begun 19 h prior to the experi-
ment. During the test, blood samples were obtained by
heparinized microcapillary tubes from the orbital sinus of
the mice at the following time intervals: 0 min (fasting
levels), and 15, 30, 60, and 120 min after glucose
administration. Glucose (2 g/kg in mice on standard
chow and 1 g/kg in mice on HFD) was given orally, using
a gavage tube. Blood glucose levels were measured by the
glucose oxidase method (Sanwa Kagaku Kenkyusho,
Nagoya, Japan). After collection, blood samples were
kept on ice and then centrifuged (3,000 rotations per
minute for 10 min at 4°C), and serum was separated. The
serum samples were used fresh or kept at 280°C until
further processing. Insulin, total GIP, and total glucagon-
like peptide 1 (GLP-1) levels were measured by ELISA as
follows: insulin kit (Shibayagi, Shibukawa, Japan), total
GIP kit (Millipore, Billerica, MA), and total GLP-1 kit
(Meso Scale Discovery, Rockville, MD).
Insulin Tolerance Test
The mice were fasted 4–6 h before the start of the exper-
iment. Blood samples were drawn from the orbital sinus
using heparinized microcapillary tubes at the following
time intervals: 0 min (fasting levels), and 15, 30, 60,
and 120 min after insulin administration. Human insulin
(100 units/mL; Eli Lilly and Co., Indianapolis, IN) was
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administered intraperitoneally in a dose of 0.5 units/kg.
Blood glucose levels were measured by the glucose oxidase
method (Sanwa Kagaku Kenkyusho).
Measurement of Body Fat Composition (Measurement
of Subcutaneous and Visceral Fat)
In young mice at the age of 7 weeks, or after 8 weeks of
feeding with a CFD or HFD, body fat was measured by
a computed tomography (CT) scan (A La Theta LCT-100;
Hitachi Aloka, Tokyo, Japan). The mice were anesthetized
with intraperitoneal injection of sodium pentobarbital
and placed in a measurement chamber of the CT scanner
in the supine position. The scanned area of the body was
ﬂanked by the xiphisternum and sacrum; the width of
scanned slices was 2 mm. The images obtained were
analyzed using A La Theta software, version 1.00, and
values for body fat, both subcutaneous and visceral, were
quantiﬁed in grams.
Indirect Calorimetry and Mice Activity
Mice were kept 6–7 weeks on CFD or HFD, and afterward
indirect calorimetry was performed and the activity of the
mice was measured (ARCO 2000 mass spectrometer;
Arco System, Chiba, Japan). Each mouse was placed in an
individual chamber with free access to water and CFD or
HFD. Respiratory quotient, energy expenditure (in calo-
ries per minute per kilogram), fat oxidation (in milligrams
per minute per kilogram), and mice activity (in counts per
minute) were measured every 5 min over 48 h.
In Vitro Insulin Secretion
For the measurement of glucose-stimulated insulin secre-
tion in vitro, islets from mice on CFD and HFD were
isolated using collagenase digestion method. In brief, mice
were killed by cervical dislocation; 0.5 mg/mL collagenase
dissolved in Hanks’ balanced salt solution was injected
through the bile duct into the pancreas, and, after its
expansion, it was manually isolated and incubated in
Krebs-Ringer bicarbonate buffer (KRBB; 120 mmol/L
NaCl, 4.7 mmol/L KCl, 1.2 mmol/L MgSO4, 1.2 mmol/L
KH2PO4, 2.4 mmol/L CaCl2, and 20 mmol/L NaHCO3) at
37°C over 21 min. After homogenizing the pancreas with
KRBB, the islets were separated by centrifugation in Ficoll
gradient. Separated islets were resuspended in KRBB
on a dish and handpicked under a light microscope. For
glucose-stimulated insulin secretion assessment, three
batches with different glucose concentrations were pre-
pared, as follows: 5.5 mmol/L glucose, 11.1 mmol/L
glucose, and 11.1 mmol/L glucose plus 100 nmol/L GIP-
human (Peptide Institute, Osaka, Japan). For each sample
containing 500 mL incubation medium (KRBB; 2 mol/L
HEPES, pH 7.4; 0.2% BSA), 10 islets were handpicked in
a volume of 200 mL KRBB and incubated at 37°C during
30 min (following preincubation in the same conditions).
For the measurement of insulin content in islets of HFD-
fed mice, samples were incubated overnight with 5 mL/g
acid ethanol (at 4°C). Insulin concentration and insulin
content were measured using radioimmunoassay (Aloka
Accuﬂex g 7000; Hitachi, Tokyo, Japan).
Measurement of b-Cell Area
Whole pancreas was isolated manually from mice kept on
CFD and HFD for 8 weeks. All isolated organs were ﬁxed
in Bouin’s solution, then were washed with 50% ethanol
once per day over 1 week, and, ﬁnally, embedded in par-
afﬁn. Every ﬁfth section of the pancreas was used for
analysis. In total, three sections (slides) per pancreas
(per mouse) were analyzed. The parafﬁn slides were
deparafﬁnized with lemosol, rehydrated with 100% and
70% ethanol, blocked by 3% peroxidase, incubated over-
night (at 4°C) in a humidiﬁed chamber with polyclonal
rabbit anti-insulin antibody (Santa Cruz Biotechnology,
Santa Cruz, CA), and conjugated with ﬂuorescent second-
ary antibody the next day. After immunostaining, all
slides were analyzed by immunoﬂuorescent microscope
(Keyence Corp., Osaka, Japan) using BZ Analyzer soft-
ware. The area of the whole pancreas and the area of
insulin-immunopositive cells were measured at the same
time. The b-cell area was expressed as b-cell area/total
pancreas area in all analyzed slides.
Statistics
All results are expressed as the mean 6 SE. Statistical
analyses were performed using ANOVA with Tukey
test, and P values ,0.05 were considered statistically
signiﬁcant.
RESULTS
GIP Reduction in GIP-GFP KI Mice
The main genetic trait of GIP-GFP KI mice is alteration
(truncation) of the prepro-GIP gene coupled with insertion
of the GFP coding sequence (15). In mice kept on stan-
dard chow, the assessment of GIP mRNA levels in the
small intestine showed reduced levels in GIPgfp/+ mice
(P , 0.05), while in GIPgfp/gfp mice, GIP mRNA could
not be detected (P , 0.05, P , 0.01) (Fig. 1A). Small in-
testine GIP contents were reduced in GIPgfp/+ mice (P ,
0.05) and were undetectable in GIPgfp/gfp mice (P , 0.01)
when compared with WT mice. Total GIP levels during
OGTT (Fig. 1B) as well as GIP secretion (as shown by the
area under the curve of GIP) (Fig. 1C) were reduced by
;50% in GIPgfp/+ mice (P , 0.01) and were below the
lower limit of detection in GIPgfp/gfp mice (P , 0.001)
compared with control WT mice (the lower detection limit
of ELISA total GIP levels kit was 8.2 pg/mL).
Body Weight Progression, Glucose Tolerance, and
b-Cell Proﬁle Following GIP Reduction in Standard
Chow-Fed Mice
Starting from 4 weeks of age, the body weight of
weaning mice fed standard chow (containing 10% fat)
was recorded, and no changes were seen among WT,
GIPgfp/+, and GIPgfp/gfp mice (Fig. 2A). The measurement
of body fat composition (body fat) in the 7th week of age
(just before placing the mice on an HFD) revealed similar
amounts of body fat in all mice (Fig. 2B). During an OGTT,
blood glucose levels were higher in GIPgfp/+ mice than those
in WT mice at 30 min (P , 0.05), whereas in GIPgfp/gfp
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mice glucose elevation persisted at 30 and 60 min (P ,
0.05) (Fig. 2C). Meanwhile, insulin levels in both GIPgfp/+
and GIPgfp/gfp remained lower in comparison with WT,
especially at 15 and 30 min after glucose load (P , 0.05)
(Fig. 2D). In vitro measurement of insulin secretion
(Fig. 2E) showed a similar pattern of secretion in all types
of mice at 5.5 mmol/L glucose, as well as at 11.1 mmol/L
glucose. When challenged with 100 nmol/L human GIP
peptide together with 11.1 mmol/L glucose, the islets of
GIP-GFP KI mice, both GIPgfp/+ and GIPgfp/gfp, exhibited
a similar insulin response to that of WT mice. GIPR
mRNA levels in b-cells remained unchanged in GIP-GFP
KI mice when compared with controls (Fig. 2F). mRNA
expression of preproglucagon, peptide YY, cholecystokinin,
somatostatin, and secretin in the small intestine showed
no differences in GIP-GFP KI mice compared with WT mice
(data not shown). Plasma GLP-1 levels during the OGTT
did not differ among the three types of mice (WT mice
15.54 6 6.8 pg/mL, GIPgfp/+ mice 11.83 6 4.97 pg/mL,
GIPgfp/gfp mice 18.54 6 3.96 pg/mL at 15 min after
OGTT).
Body weight follow-up of mice on CFD in a period of
8 weeks (starting at the age of 7 weeks) showed that the
body weight progression did not differ among all three
groups of mice (Supplementary Fig. 1A). The overall glu-
cose response to 0.5 units/kg human insulin (insulin tol-
erance test [ITT] data) was similar in WT, GIPgfp/+, and
GIPgfp/gfp mice at almost all time points of the experiment
(at 60 min of ITT, GIPgfp/gfp mice had lower blood glu-
cose levels when compared with WT mice) (Supplementary
Fig. 1B).
Bone Formation in Conditions of Standard Chow
Feeding
Following GIP reduction, the bone volume in GIPgfp/+ mice
was similar to that in WT mice, whereas GIPgfp/gfp mice
had reduced bone volume (P , 0.05) (Fig. 3A). Further-
more, the number of trabeculae in GIPgfp/+ mice showed
no changes when compared with WT mice, while GIPgfp/gfp
mice exhibited a decrease (P , 0.05) (Fig. 3C), as demon-
strated by the images of proximal tibial sections (Fig. 3B).
Although osteoblast surface was decreased in GIPgfp/+ mice
compared with WT mice (P , 0.05) (Fig. 3D), the bone
formation rate (Fig. 3F) remained unchanged in these
mice. The osteoclast surface was increased in GIPgfp/gfp
mice (P , 0.05) when compared with WT mice, while in
GIPgfp/+ mice it remained similar to WT mice (Fig. 3E).
Induction of Metabolic Stress by HFD
Figures 4 and 5 describe the phenotype changes induced
by HFD feeding for 8 weeks (56 days). Starting from the
second week of HFD feeding, WT mice steadily increased
their body weight (P , 0.001) compared with the lean
control (Fig. 4A), while within the HFD group, GIPgfp/+
mice showed less body weight gain (P, 0.01 at 2nd week;
P , 0.001 at 8th week) than WT mice; GIPgfp/gfp mice
exhibited the lowest body weight gain (P , 0.001 at 2nd
week; P , 0.001 at 8th week vs. WT HFD). Ad libitum
glucose levels were measured at the same time, once per
week, and the overall glucose levels in all mice remained
similar (Fig. 4B). Food and water intake were similar in all
groups of mice (data not shown).
During OGTT, total GIP levels and GIP secretion were
increased twofold in WT mice on HFD (P , 0.001) com-
pared with the lean control; in HFD-fed mice, GIPgfp/+
mice exhibited decreased levels (P , 0.05), while GIPgfp/gfp
mice showed an absence of GIP (P , 0.001) (Fig. 4C and
D). Fasting glucose levels in WT mice on HFD were higher
(P , 0.01) when compared with their lean littermates; on
HFD background, glucose levels remained similar in all
mice (Fig. 4E). The overall insulin response (Fig. 4F) in
WT mice on HFD was more intense than that of the
control mice, and, within the HFD group, the insulin lev-
els of GIPgfp/+ mice remained lower in comparison with
those of WT mice (P , 0.05), while GIPgfp/gfp mice
showed the lowest insulin levels (P , 0.01, P , 0.001).
Insulin secretion in vitro (Fig. 4G) was similar among all
mice on CFD and HFD in the presence of 5.5 mmol/L
glucose. In response to 11.1 mmol/L glucose, WT mice
on HFD had higher insulin secretion compared with WT
mice on CFD, whereas in the HFD group similar levels
were found in WT and GIPgfp/+ mice, coupled with lower
Figure 1—GIP reduction in GIP-GFP KI mice. A: The following
measurements were conducted in the small intestine of WT,
GIPgfp/+, and GIPgfp/gfp mice: assessment of GIP mRNA levels
(expressed as GIPR mRNA/GAPDH mRNA) and GIP content (ex-
pressed as GIP/protein content). Total GIP levels (B) and GIP se-
cretion (the area under the curve of GIP) (C) were measured during
the OGTT (glucose 2 g/kg body weight). n = 5–6 per group. WT mice
are represented by white bars and white circles, GIPgfp/+ mice are
represented by black bars and black squares, and GIPgfp/gfp mice are
represented by gray bars and gray triangles. *P < 0.05, **P < 0.01,
***P < 0.001.
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insulin levels in GIPgfp/gfp mice (P , 0.05 vs. WT HFD,
P , 0.01 vs. GIPgfp/+). When 100 nmol/L human GIP
peptide was added to 11.1 mmol/L glucose, insulin secre-
tion remained lower in GIPgfp/gfp mice on HFD (P , 0.01).
Measurement of the b-cell area, as expressed by the ratio
of b-cell area to total pancreas area, showed a tendency
toward an increase observed in HFD-fed mice, relative to
the lean mice, although the difference was not statisti-
cally signiﬁcant. However, within the HFD group, b-cell
area remained similar in WT and GIPgfp/+ mice, while
GIPgfp/gfp mice exhibited decreased b-cell area (P , 0.05)
(Fig. 4H). The expression levels of GIPR mRNA in the
islets were similar in WT mice on CFD and HFD, as well
as in GIPgfp/+ mice on HFD, whereas in GIPgfp/gfp mice
levels were reduced (P , 0.01 vs. GIPgfp/+) (Fig. 4I).
Adipose Tissue Response to HFD Feeding and
Consequential Energy Expenditure Changes
CT scan measurement (Fig. 5A) of visceral, subcutaneous,
and total body fat demonstrated a large increase in fat
accumulation in WT mice on HFD (P , 0.01) when com-
pared with the lean mice. On an HFD background, WT
Figure 2—Body weight, glucose tolerance, and b-cell proﬁle following GIP reduction in standard chow-fed mice. A: Body weight of
weaning mice (4 weeks old) was measured starting from the beginning of the weaning period until the age of 8 weeks (body weight in
the 7th week of age was not measured because of CT scan measurement and postanesthesia recovery period). B: Body fat was measured
by CT scan in the 7th week of age. Glucose (C) and insulin (D) levels were measured during OGTT (glucose load of 2 g/kg body weight). E: In
vitro insulin secretion from isolated islets was measured in conditions of 5.5 mmol/L glucose, 11.1 mmol/L glucose, and 11.1 mmol/L
glucose plus 100 nmol/L human GIP. F: GIPR mRNA levels in islets were expressed as GIPR mRNA/GAPDH mRNA. n = 5–6 mice or
samples per group; 10 islets per sample. WT mice are represented by white circles and white bars, GIPgfp/+ mice are represented by black
squares and black bars, and GIPgfp/gfp mice are represented by gray triangles and gray bars. *P < 0.05, **P < 0.01 vs. WT; #P < 0.05 vs.
GIPgfp/+ mice.
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mice accumulated more body fat than their GIPgfp/+ lit-
termates (P , 0.05), while the fat depots in GIPgfp/gfp
were greatly reduced (P , 0.01), showing levels similar
to the lean control. The CT scan images of abdominal
sections of mice on CFD and HFD visualize the difference
in fat accumulation among all groups. Assessment of in-
sulin resistance by ITT (Fig. 5B) showed a rise in glucose
levels in HFD-fed WT mice compared with lean mice,
while within the HFD group a better response to insulin
was observed in both GIPgfp/+ and GIPgfp/gfp mice, with
glucose levels remaining lower (P , 0.05; P , 0.01) com-
pared with WT mice. In relation to these data, a tendency
toward increased fat oxidation (Fig. 5C) in all mice on
HFD was observed (P , 0.05), with a larger increase in
GIPgfp/+ mice (P , 0.05), especially in the dark phase, and
even higher in GIPgfp/gfp mice (P , 0.05). In addition, the
energy expenditure measurement on HFD background
(Fig. 5D) showed an increase in GIPgfp/+ mice (P ,
0.05) (again, more prominent in the dark phase) and in
GIPgfp/gfp mice (P , 0.05) when compared with WT mice.
Concomitantly, mice activity was measured (Fig. 5E), and
no statistically signiﬁcant changes were found in the HFD
group. Expression levels of GIPR mRNA in white (visceral)
adipose tissue (Fig. 5F) remained unchanged in all animals
on CFD and HFD, except for GIPgfp/gfp mice, in which the
levels were elevated (P , 0.05).
DISCUSSION
Studies in single and double incretin receptor knock-out
mice (16) have shown that, although secretion of GIP and
GLP-1 is triggered by different factors, they have an ad-
ditive stimulating effect on b-cells with regard to insulin
secretion, with GIP accounting for the larger portion of
the total incretin effect in male mice. Furthermore, hu-
man data demonstrated that after an oral glucose load of
75 g and a mixed meal load (17,18), secretion of GIP is
more pronounced than GLP-1 secretion, suggesting that
GIP may play a more potent role in the regulation of
postprandial insulin secretion in nondiabetic conditions.
We have generated GIP-GFP KI mice characterized by
truncation of the prepro-GIP gene and insertion of the
GFP coding sequence that leads to reduced GIP produc-
tion in heterozygous state and the absence of GIP pro-
duction in the homozygous state. GIPgfp/gfp mice exhibit
a phenotype similar to that of GIPRKO mice regarding
glucose tolerance, bone formation, and adipose tissue ex-
pansion (Table 1). However, GIPgfp/+ mice represent a novel
mouse model in which GIP, despite its secretion being re-
duced by half, maintains glucose levels similar to those of
controls (Fig. 4B and E) and lessens insulin resistance in
mice with HFD-induced obesity (Figs. 4F and 5B).
When fed standard chow, GIPgfp/gfp mice, in a manner
similar to GIPRKO mice, had higher glucose excursions
accompanied with insufﬁcient production of insulin dur-
ing OGTT (Table 1). Despite having reduced, but still
present, GIP secretion, GIPgfp/+ mice also showed mild
glucose intolerance and lower insulin secretion, conﬁrm-
ing the potent insulinotropic effect of GIP (Fig. 2C and D,
and Table 1). Furthermore, insulin secretion tests in vitro
Figure 3—Bone formation in conditions of standard chow feeding. The following parameters were measured by bone histomorphometry:
bone volume (expressed as bone volume %) (A), trabeculae number (expressed as number per millimeter) (C), osteoblast surface (%) (D),
osteoclast surface (%) (E), and bone formation rate (%/year) (F ). B: Images display trabeculae of proximal tibial sections taken from 6-week-
old mice. n = 5–6 per group. WT mice are represented by white bars, GIPgfp/+ mice are represented by black bars, and GIPgfp/gfp mice are
represented by gray bars. *P < 0.05 vs. WT mice. The absence of an asterisk above the horizontal brackets in A and C–E indicates no
statistical signiﬁcance.
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Figure 4—Induction of metabolic stress by HFD. Body weight (A) and ad libitum glucose levels (B) in WT CFD, WT HFD, GIPgfp/+ HFD, and
GIPgfp/gfp HFD mice were measured once per week during 8 weeks (56 days) of feeding with CFD (10% of fat) or HFD (60% of fat). Total GIP
levels (C), GIP secretion (GIP area under the curve) (D), glucose levels (E ), and insulin levels (F ) were measured during OGTT (glucose load
of 1 g/kg body weight) conducted after 8 weeks (56 days) of CFD or HFD feeding. G: In vitro insulin secretion from isolated islets was
measured in conditions of 5.5 mmol/L glucose, 11.1 mmol/L glucose, and 11.1 mmol/L glucose plus 100 nmol/L human GIP. Results were
expressed as insulin secretion (% insulin content). H: b-Cell area was measured by immunohistochemistry of pancreas sections and
subsequent analysis using BZ Analyzer software. Results are expressed as b-cell area/total pancreas area. I: GIPR mRNA levels in islets
were expressed as GIPR mRNA/GAPDH mRNA. n = 5–6 mice or samples per group; 10 islets per sample. WT CFD mice are represented by
white circles with square dot dash and white bars with square dot border, WT HFD mice are represented by white circles with solid dash
and white bars with solid border, GIPgfp/+ mice are represented by black squares and black bars, and GIPgfp/gfp mice are represented by
gray triangles and gray bars. P values are expressed as follows: A, C–F: *P < 0.05, **P < 0.01, ***P < 0.001 vs. WT HFD; B: *P < 0.05 WT
CFD vs. WT HFD; and #P < 0.05 GIPgfp/+ HFD vs. WT HFD; G–I: *P < 0.05, **P < 0.01, ***P < 0.001. The absence of an asterisk above the
horizontal brackets in G–I indicates no statistical signiﬁcance.
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demonstrated a similar pattern of secretion in all groups
of mice. The measurement of mRNA expression levels of
GIPR in the islets showed no changes among all groups of
mice, indicating the presence of functional GIPRs.
Similar to GIP-lacking and GIP-reduced mice, rat GIP
promoter-diphtheria toxin A chain transgenic mice exhibit
glucose intolerance, in their case very profound, with
complete abolition of the incretin effect, and show
similarities in phenotype under HFD conditions (19). In
this mouse model (GIP promoter-diphtheria toxin A chain),
forced expression of attenuated diphtheria toxin was estab-
lished under the rat GIP promoter, leading to isolated
Figure 5—Adipose tissue response to HFD feeding and consequential energy expenditure changes. A: Visceral, subcutaneous, and total
fat (expressed in grams) in WT CFD, WT HFD, GIPgfp/+HFD, and GIPgfp/gfp HFD mice were measured, and CT images of transverse
abdominal sections were taken after 8 weeks of feeding with CFD (10% of fat) or HFD (60% of fat). B: ITT (insulin 0.5 units/kg of body
weight) was conducted after 8 weeks of CFD or HFD. Fat oxidation (in milligrams per minute per kilogram) (C), energy expenditure (calories
per minute per kilogram) (D), and mice activity (counts per minute) (E) were measured after 6–7 weeks of CFD or HFD. F: GIPR mRNA levels
in white (visceral) adipose tissue were expressed as GIPR mRNA/GAPDH mRNA. n = 5–6 mice or samples per group. WT CFD mice are
represented by white bars with square dot border and white circles with square dot dash; WT HFD mice are represented by white bars with
solid border and white circles with solid dash; GIPgfp/+ HFD mice are represented by black bars and black squares; and GIPgfp/gfp HFD mice
are represented by gray bars and gray triangles. P values are expressed as follows: B: *P< 0.05, **P< 0.01, ***P< 0.001 vs. WT HFD; A, C,
D, and F: *P < 0.05, **P < 0.01. The absence of an asterisk above the horizontal brackets in A, C, D, and F indicates no statistical
signiﬁcance.
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ablation of GIP-producing cells, and, subsequently, the ab-
sence of GIP mRNA transcripts and absence of circulating
GIP levels. However, there are reports conﬁrming the ex-
istence of double incretin-positive cells (K/L cells) in the
intestine (20), and the existence of populations of K cells
that coexpress not only GIP but also glucagon, somato-
statin, secretin, and, to a smaller extent, some other hor-
mones (21,22). Therefore, the ablation of K cells might
affect the number and/or distribution of these cell popula-
tions and could inﬂuence the accurate assessment of secre-
tion of various intestinal hormones. In the case of GIP-GFP
KI mice, the truncation of the prepro-GIP gene and expres-
sion of GIP-GFP fusion protein were driven by native GIP
promoter, enabling selective changes in K cells that affect
only GIP secretion and, even more importantly, control of
the levels of GIP production. The expression levels of
mRNA of the intestinal hormones preproglucagon, pep-
tide YY, cholecystokinin, somatostatin, and secretin were
not changed, conﬁrming that GIP reduction did not in-
terfere with their gene expression.
There are reports demonstrating that GIP induces
GLP-1 secretion (23,24). Previously conducted studies of
disrupted or blocked GIPR signaling (7,16,19) did not
yield data regarding the secretion of GLP-1. In our study,
plasma GLP-1 levels remained unchanged in GIP-GFP KI
mice, as reported earlier in a model of GIPR antagonism
(14), indicating that the reduction of GIP secretion does
not affect GLP-1 secretion. Overall, GIP-reduced mice
kept on standard chow after birth did not exhibit visible
abnormalities regarding mating potential, pregnancy,
offspring viability, growth, organ composition, and feed-
ing behavior (data not shown). Measurement of their
body weight from the beginning of the weaning period
(Fig. 2A) until just before the shift to HFD, as well as
longer-term measurement (Supplementary Fig. 1A),
showed that they are not different from their WT lit-
termates when fed a standard diet. Body fat measured
before the start of the HFD was similar between WT
and GIP-GFP KI mice. ITT showed that their insulin
sensitivity remained similar to the WT mice (Supple-
mentary Fig. 1B).
In addition to its insulinotropic role, GIP is involved in
modulation of bone formation. There are GIP-speciﬁc
receptors located on osteoblasts (25) and osteoclasts (26).
GIP operates as an anabolic hormone in the bone, where it
stimulates incorporation of meal-derived Ca2+ into bone
and bone building (13), and reduces bone absorption by
inhibiting osteoclastic activity. Studies in GIPRKO mice
have shown that the absence of GIPR signaling leads to
signiﬁcant osteoporosis due to lower osteoblast and
higher osteoclast action (13). Similar to GIPRKO mice,
GIP-lacking mice also showed signs of osteoporosis, man-
ifested by reduced bone volume, reduced number of tra-
beculae, and increased osteoclast surface. On the other
hand, GIP-reduced mice maintained normal bone volume
and bone trabeculae, and, despite the exhibited reduction
of osteoblast surface, no increased osteoclast activity was
observed. More importantly, the bone formation rate
remained normal, indicating that reduction of GIP by
;50% does not signiﬁcantly impair the beneﬁcial role
of GIP in bone formation. Considering the glucose intol-
erance of these mice, it appears that reduction of GIP
secretion more profoundly affects the insulin-potentiating
role of GIP, indicating differing regulatory mechanisms of
GIP action in b-cells and in bone (Table 1).
To better understand the extent of the phenotypic
consequences following GIP reduction, we induced
chronic metabolic stress by feeding the mice with HFD.
Previous reports indicate a strong connection between
GIP secretion and obesity in HFD-feeding conditions
(27). High caloric intake causes hypersecretion of GIP
(12,28,29) due to hyperexpression of the GIP gene (15)
and a subsequent rise in insulin secretion (30), leading to
increased fat deposition in the adipose tissue and expan-
sion of fat depots (31,32). GIP increases the adipose tis-
sue volume directly (33,34) by binding to its receptors
located on the adipocytes and indirectly by potentiating
b-cell secretion of insulin, which is known to be involved
in adipocyte fat deposition (35). In our study, HFD feed-
ing for at least 8 weeks resulted in the absence of circu-
lating GIP levels in GIP-lacking mice (consistent with data
from standard chow-fed mice), whereas in GIP-reduced
Table 1—Phenotype comparison of GIP-GFP KI mice and GIPRKO mice
Genotype/phenotype GIPgfp/+ GIPgfp/+ HFD GIPgfp/gfp GIPgfp/gfp HFD
GIPRKO
(7,13) GIPRKO HFD (6,12,29)
Standard chow feeding
GIP secretion ↓ (;50%) Absent ↑
Glucose tolerance Impaired Impaired Impaired
Bone volume ↔ ↓ ↓
HFD feeding
Glucose tolerance ↔ ↔ Impaired
Body weight ↓ ↓↓ ↓↓
Fat mass ↓ ↓↓ ↓↓
Insulin sensitivity ↑ ↑↑ ↑↑
Standard chow feeding data are relative to WT; HFD feeding data are relative to WT HFD. ↔, no changes; ↓, decreased; ↓↓, highly
decreased; ↑, increased; ↑↑, highly increased.
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mice, the reduction of GIP was similar to the levels ob-
served in lean WT mice and was lower when compared
with WT mice on HFD. The most obvious consequence of
HFD was a change in body weight and fat mass in WT
and GIP-GFP KI mice (Figs. 4A and 5A, and Table 1).
Although WT mice showed overt obesity, GIP-lacking
mice retained their body weight and fat mass at levels
similar to those of their lean littermates, as previously
reported in GIPRKO mice, in mice with K-cell ablation
(19) and in mice with chemical inhibition of GIPR sig-
naling (14). GIP-reduced mice also maintained lower
body weight throughout the experiment period of 56
days, indicating that while the lack of body weight gain
and fat mass was not as evident as it was in GIP-lacking
mice, the reduced obesity was nevertheless important.
Moreover, the glucose response to insulin during ITT
showed lower levels in both GIP-reduced and GIP-lacking
mice fed HFD, indicating that not only complete but also
partial reduction of GIP alleviates insulin resistance
while reducing obesity. Thus, a reduction of GIP secre-
tion as shown in GIP-reduced mice mitigates both direct
and indirect actions of GIP on adipose tissue and leads to
reduced diet-induced obesity.
Glucose levels measured ad libitum throughout most of
the experiment period were similar in WT mice and GIP-
GFP KI mice, and glucose excursions during OGTT
remained similar as well in all mice under HFD con-
ditions. However, all HFD-fed mice had higher OGTT
glucose levels when compared with the lean controls,
suggesting that when metabolic stress was introduced,
glucoregulation was similarly achieved in conditions of
normal and reduced GIP production. At the same time,
the circulating insulin levels were lower in GIP-lacking
and GIP-reduced mice than those of WT mice on HFD,
accompanied by decreased insulin resistance (Fig. 5B and
Table 1). These data are in line with those of a previous
study (36) examining the role of insulin in obesity and
showing that, on an obese background, the reduction of
insulin does not necessarily cause severe disturbance in
blood glucose levels. The origins of the reduced insulin
secretion are associated not only with reduced GIP signal-
ing in b-cells, but also with changes in their area as well.
Although GIP-reduced mice had a b-cell area similar to
their WT counterparts on HFD, GIP-lacking mice had
clearly fewer b-cells. Furthermore, in vitro islet studies
found that the responsiveness of b-cells to glucose in
GIP-reduced mice was similar to that in WT mice on
HFD and was higher than that of the control mice. On
the other hand, GIP-lacking mice had reduced insulin
response to glucose, suggesting that reduction of GIP
secretion might affect the ability of b-cells to respond
adequately to GIP, but not as profoundly as in cases of
complete absence of GIP secretion or GIPR signaling.
Measurement of GIPR mRNA levels in the islets revealed
similar values in WT and GIP-reduced mice, while GIP-
lacking mice exhibited decreased expression of GIPR
mRNA. GIPR mRNA expression levels in the adipose
tissue did not show changes in WT and GIP-reduced
mice, but, interestingly, they were increased in GIP-lacking
mice, which is inconsistent with the islet data. Al-
though previous studies have extensively addressed dis-
ruption of GIPR signaling, our GIP-lacking mice show
for the ﬁrst time a condition of complete lack of GIP
secretion from intact K cells and might be useful in fur-
ther studies.
We have investigated the mechanism of regulation of
glucose homeostasis and reduced obesity in GIP-GFP KI
on HFD. Previously, we reported an increase in fat
oxidation and energy expenditure in GIPRKO mice fed
HFD for a short period (37) and in GIPRKO mice with
diminished insulin signaling (insulin receptor substrate
1 KO/GIPRKO mice) (38), indicating that increased fat
oxidation accounts for the reduction of obesity in the
absence of GIPR signaling. The current study has demon-
strated increased fat oxidation in GIP-reduced mice, and,
even more intensely, in GIP-lacking mice. This phenome-
non might occur because of increased adiponectin levels
via peroxisome proliferator–activated receptor a levels in
the adipose tissue (37) or because of increased activity of
the enzymes involved in b-oxidation in the liver, such as
cluster of differentiation 36 and mitochondrial uncou-
pling protein 2 (38). GIP-lacking and GIP-reduced mice
also exhibited higher energy expenditure while on
an HFD. There are reports showing that increased energy
expenditure is coupled with increased locomotor activity;
disruption of GIPR signaling increases the activity of mice
not only under HFD conditions, as in mice treated with
GIPR antagonist (14) and GIPRKO mice (12), but also
leads to increased spontaneous activity even during stan-
dard diet feeding, as described in double incretin receptor
KO mice (29) and in adult or aged GIPRKO mice (39,40).
Consistent with these data, GIP-lacking and GIP-reduced
mice also exhibited a tendency toward increased activity,
especially in the dark phase, although without a statisti-
cally signiﬁcant difference.
In conclusion, our data suggest that the reduction of
GIP secretion in vivo conﬁrms the potent role of GIP in
insulin secretion and leads to reduced obesity and reduced
insulin resistance in HFD conditions without severely
impairing glucose homeostasis and without disrupting the
role of GIP in bone formation. These ﬁndings are
potentially promising for a new therapeutic approach to
obesity and type 2 diabetes.
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